Anzeige
Meldung des Tages: Golden Cross bestätigt ein Fosterville-ähnliches System — und jetzt wird tiefer gebohrt

Biogen News

Aktie
WKN:  789617 ISIN:  US09062X1037 US-Symbol:  BIIB Branche:  Pharmazeutika Land:  USA
Keine aktuellen Kursdaten verfügbar
Depot/Watchlist
Marktkapitalisierung *
22,04 Mrd. €
Streubesitz
3,72%
KGV
11,76
Nachhaltigkeits-Score
49 %
Index-Zuordnung
Nasdaq 100
Weiter aufwärts? Long handeln - Jetzt mit Hebel 5,48: UQ3YDK
Werbung

Biogen News

29.09.25 - GlobeNewswire
“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in China
TOKYO and CAMBRIDGE, Mass., Sept. 28, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate ...
25.09.25 - dpa-AFX
EU erteilt Zulassung für Alzheimer-Medikament von Eli Lilly
Für einen Teil der Menschen mit Alzheimer im Frühstadium gibt es in der EU eine weitere Behandlungsmöglichkeit. Die zuständige Europäische Kommission erteilte dem ...
24.09.25 - GlobeNewswire
LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Australia
TOKYO and CAMBRIDGE, Mass., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate ...
23.09.25 - GlobeNewswire
Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen
CAMBRIDGE, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) issued a Complete ...
18.09.25 - GlobeNewswire
Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates
Biogen to drive end-​to-end development and commercialization of ThecaFlex DRx™, an investigational implantable device for intrathecal delivery of antisense oligonucleotides (ASOs) ...
17.09.25 - GlobeNewswire
Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe
Postpartum depression is a leading cause of maternal mortality in Europe 1-2 , and is one of the most common medical conditions associated with pregnancy 3-5 ; up to 20% of ...
17.09.25 - dpa-AFX
Biogen-Medikament gegen Wochenbettdepression in der EU zugelassen
Frauen mit Wochenbettdepression haben in der EU künftig Zugang zu einem neuen Medikament. Die Europäische Kommission hat Zuranolon vom US-​Konzern Biogen die EU-...
03.09.25 - GlobeNewswire
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status
LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-​amyloid treatment to offer at-home injection from the start to help patients and care partners treat this ...
02.09.25 - PR Newswire
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-​irmb) as a Subcutaneous Starting Dose for the Treatment of ...
02.09.25 - GlobeNewswire
Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome
– Durable reductions in seizures and continuing improvements in cognition and behavior through 3 years in patients who continued to receive zorevunersen in the open-​label ...
30.08.25 - dpa-AFX
Marktstart für Alzheimer-Mittel Lecanemab in Deutschland
Der zur Alzheimer-​Therapie zugelassene Antikörper Lecanemab kommt am 1. September in Deutschland offiziell auf den Markt. Österreich und Deutschland seien die ersten EU-...
30.08.25 wallstreetONLINE Redaktion
Börsen-Nieten im Fokus: Diese 10 S&P-500-Aktien haben ein Jahrzehnt lang nur enttäuscht – bis jetzt!
Langfristige Verluste sind im S&P 500 eine Seltenheit – doch zehn Aktien haben in den vergangenen zehn Jahren klar enttäuscht. Welche dieser Nachzügler jetzt mit starken ...
29.08.25 - GlobeNewswire
FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease
LEQEMBI IQLIK is the first and only anti-​amyloid treatment to offer an at-home injection to help patients and care partners continue to treat this progressive, relentless disease after ...
29.08.25 - PR Newswire
/U P D A T E -- Eisai Inc./
/U P D A T E -- Eisai Inc./ PR Newswire
25.08.25 - GlobeNewswire
Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress
– 3-year data from open-​label extension (OLE) studies demonstrate the potential for disease modification with durable seizure reductions and improvements in cognition and ...
25.08.25 - GlobeNewswire
Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI® (lecanemab)
TOKYO and CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate ...
11.08.25 - GlobeNewswire
Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome
– Global, pivotal Phase 3 study will evaluate efficacy and safety of zorevunersen compared to sham over a 52-week treatment period –
31.07.25 wallstreetONLINE Redaktion
Ihre wichtigsten Termine: Heute im Blick: Amazon.com, Mastercard, Apple, AbbVie, BMW, Rolls-Royce, Ferrari
Gut geplant in den Tag. Mit dem wO-​Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine ...
30.07.25 - PR Newswire
Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025
Two-Year Real-​World Study of LEQEMBI® in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025 PR Newswire
30.07.25 - PR Newswire
New Data Presented at AAIC Demonstrates Investigational LEQEMBI® (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer's Disease
New Data Presented at AAIC Demonstrates Investigational LEQEMBI® (lecanemab-​irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing ...

Newssuche

Videos

newspaper
03.04.26
RW QUANTUM Strategie Einführung
Am Sonntag, den 12.4.26 wird erstmals die RW QUANTUM Strategie geschult. Der Ansatz handelt die ... Mehr »